A national vaccination program against hepatitis B virus (HBV) to immunize every newborn was initiated in Taiwan in 1986. A serologic survey of 1,812 fully vaccinated children residing in four aboriginal villages and four adjacent nonaboriginal Han Chinese rural villages was conducted in 1993. Children in three of the four aboriginal villages had significantly lower titers of antibody against hepatitis B surface antigen (anti-HBs) than did children in the nonaboriginal villages. Evaluation of cold chain operation for vaccine storage and transport suggested that cold chain failure was not responsible for the fact that children residing in the more remote aboriginal villages had lower mean trters of anti-HBs. However, children whose parents were both aborigines had lower anti-HBs mean trter than did children whose parents were both ethnic Han Chinese. Children of mixed parental origins had intermediate mean titer of anti-HBs. Serologic responses to Japanese encephalitis virus and diphtheria vaccines did not show such correlation with ethnic groups, indicating that the determinant for HBV hyporesponsiveness among the aboriginal children is distinct from that of other childhood vaccines. It was therefore concluded that host factors pertaining to ethnic origin might be responsible for the hyporesponsiveness to HBV vaccine in the aboriginal populations. This finding, if substantiated with further prospective studies, might provide possible means for more targeted trials to improve vaccine response and to reduce vaccine failure among these well-defined ethnic groups. Am J Epidemiol 1996;143:718-24.
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antibodies; diphtheria; encephalitis viruses, Japanese; ethnic groups; hepatitis B vaccines; hepatitis B virus Administration of hepatitis B virus (HBV) vaccine is the most effective means for prevention of HBV (1-3). The vaccine has repeatedly been demonstrated to be highly efficacious in inducing adequate levels of antibody against surface antigen (anti-HBs)-protective antibody, but a fraction of vaccinees mounts a poor immune response or no response at all (1, 2, 4, 5). Many factors have been shown to hinder HBV immune response, including advanced age, consumption of alcohol and nicotine (6) (7) (8) , chronic diseases (9, 10), and genetic determinants (11, 12) . These factors, except for genetic makeup, have been derived mostly from studies of adults and are much less pertinent to child vaccinees.
In areas of hyperendemic HBV infection, such as Taiwan and many other Asian and African countries, induction of protective immunity through use of HBV vaccine during early infancy is paramount to prevent perinatal transmission, which is responsible for the majority of chronic HBV carriers (13) (14) (15) . Despite proper and timely administration of HBV vaccines, primary failure occurs in some infants as in adults and results either in a lack of satisfactory immune response or in chronic HBV infection (2) . The accumulation of a certain fraction of each birth cohort lacking HBV protective immunity could potentially pose a threat to long-term, successful control of HBV transmission through vaccine use. Identifying predictors of low responsiveness and targeting means to circumvent primary vaccine failure in these newboms remain urgent challenges. In a seroepidemiologic survey of HBV among vaccinated children in several aboriginal and nonaboriginal rural villages in Taiwan, we noted that levels of protective anti-HBs differed between villages. Investigations were carried out to distinguish factors pertaining to the host or to the vaccines that might be responsible for hyporesponsiveness to HBV vaccine.
MATERIALS AND METHODS

Subjects and immunization
A seroepidemiologic study of HBV profile was conducted in 1,812 fully vaccinated children aged 3-6 years who resided in four aboriginal villages, one each in northern, southern, central, and eastern Taiwan, and four adjacent nonaboriginal rural villages. Aboriginal villages are defined by the Census Bureau of Taiwan as villages in which over 52 percent of the residents are registered as aborigines. The populations of the adjacent rural nonaboriginal villages are mostly ethnic Han Chinese. The selection of rural villages was based on convenience, but the sampling of children within each village followed a systematic stratified sampling according to each age group on the basis of the census information. All children received four doses (5 /ig/ dose) of plasma-derived HBV vaccine (Hevac B, Pasteur-Lifeguard, Taiwan) intramuscularly at 1, 5, and 9 weeks after birth and at age 12 months. Since natural HBV infections can boost anti-HBS levels, any child whose serologic tests indicated a history of natural HBV infection, i.e., either a positive hepatitis B surface antigen (HBsAg) (n -65) and/or antibody against core antigen (n -133), was excluded from the analysis because the emphasis of this investigation was to study the host response to HBV vaccine by using anti-HBs level as an indicator.
A serum sample was collected from each child. Demographic information and HBV vaccination history were extracted from the immunization records at the local health station where vaccines are administered free to all children. Immunization records at the local health station routinely include only the active immunization history; the history of hyperimmune globulin administration at birth and the maternal HBV serologic profile were available at the local health station for only a fraction of the children. The parental ethnic origins of these children were obtained by a follow-up questionnaire in 1994, 18 months after the initial serosurvey. Parental ethnic origins could be obtained for 1,108 children (61.1 percent).
HBV serology
Detection of HBsAg and anti-HBs or HBV core protein was carried out using commercially available radioimmunoassay kits (AUSRIAAI, AUSAB, CORAB, Abbott Laboratories, North Chicago, Illinois). Quantitation of anti-HBs was carried out by radioimmunoassay testing of serial dilutions of the samples along with serial dilutions of a standard serum containing a known quantity (in IU/liter) of hypoimmune globulin against HBV. Antibodies against Japanese encephalitis virus (JEV) and diphtheria among children who received the full series (three doses) of JEV vaccination and the combination vaccine of diphtheria, pertussis, and tetanus were measured as general indicators of the children's ability to mount B cell immunologic responses. Antibody against JEV was measured by plaque reduction neutralization test, and antibody against diphtheria toxin was measured by in vitro neutralization of toxin using Vero cell cytotoxicity as an indicator (16) . In Taiwan, natural infection with JEV occurs so that JEV antibody in each child is boosted with increasing age beginning at age 4 to 5 years (L. C. Hsu, National Institute of Preventive Medicine, unpublished data). Therefore, only 3-yearold children were included in the analysis to study the host response to JEV vaccination.
Cold chain evaluation
Routine monitoring of the cold chain operation was initiated in 1991 by testing the virus titers of two live vaccines, i.e., polio and measles, and is carried out by the National Bureau of Food and Drug, Taipei, Taiwan. Both vaccines were randomly collected from selected vaccine administration sites throughout the island. The measles and polio vaccines were grown in Vero and Hep2 cells, respectively, to determine virus content, expressed as the quantity of a virus suspension that will infect 50 percent of cell cultures (CCJD 50 ). The two villages in the eastern region in this study had been selected for cold chain evaluation in 1992 through 1993; therefore, CCJD 50 values for polio and measles vaccines determined at that time were used as surrogates to evaluate the cold chain operation in these two villages.
Data analysis
All collected information, including serologic results and immunization history for HBV, JEV, and diphtheria was compiled in a computerized format and analyzed using Statistical Software (SAS Institute, Inc., Cary, North Carolina). Chi-square, MantelHaenszel test for trend, and Z test were used as measures of significance. Multivariate linear regression models and logistic regression model were constructed to simultaneously examine multiple factors mat might influence the anti-HBs titer.
RESULTS
A total of 881 male and 791 female fully vaccinated children were included in the analysis. The mean titers of anti-HBs in the four nonaboriginal villages were Am J Epidemiol Vol. 143, No. 7, 1996 comparable with one another, but were significantly higher than those of three of the four aboriginal villages (table 1) . The children in the aboriginal village located in central Taiwan had a higher mean titer of anti-HBS than did children in other regions, and the distribution of the titers was similar to that of the children in the four nonaboriginal villages.
To examine whether a less satisfactory cold chain operation in the more remote aboriginal villages might have been the cause of the apparent lower herd immunity among children residing in aboriginal areas, we obtained the available data on CCID 50 for the two villages (one aboriginal and one nonaboriginal) in the eastern region (table 2). The residual titers for the two live vaccines randomly obtained from the local health station indicated that the conditions of the vaccine storage were equally satisfactory for both the aboriginal and the nonaboriginal villages. In contrast, the anti-HBS titers were significantly higher in children from the nonaboriginal village than in children from the aboriginal village (chi-square, p < 0.05), suggesting that cold chain failure is unlikely to be the cause of the aboriginal village having a lower herd immunity to the HBV vaccine, at least in the eastern region.
Since some ethnic Han families reside in the aboriginal villages, and vice versa, whenever possible the maternal and paternal ethnic origins of each child were obtained to examine whether host factors pertaining to ethnic origins could have contributed to the differential anti-HBs titers in the Han and aboriginal children (table 3). In the central region, where children in the aboriginal village had as high an antibody response as the children in the nonaboriginal village, as many as 57.7 percent of children had parents who were both ethnic Han in origin, whereas more than 90 percent of children in the other three aboriginal villages were offspring of two aboriginal parents, and the Han Chinese contributed only a very minor fraction to the population.
The anti-HBs titers were further analyzed according to the ethnic origins of both parents for the 1,108 children whose parental origins could be clearly identified as both aborigines, both ethnic Han, or mixed (table 4) . Despite the wide range of anti-HBs titers among the children, the pure Han children had the highest mean titer, 53.7 IU/liter, the pure aboriginal children had a mean anti-HBs titer of 38.1 IU/liter, and the difference between these two groups was statistically significant (Student's t test, p < 0.001). Furthermore, children with mixed origins had an intermediate mean titer of 45.6 IU/liter. The distribution of the anti-HBs titer was such that pure aboriginal children had the highest fraction of those who possessed a lower-than-protective level of anti-HBs (<10 IU/liter), whereas children whose parents were both Han had the lowest fraction of those who possessed an anti-HBs titer of less than 10 IU/liter. The titers of the children with mixed parental origins fell in-between the other two groups. The fraction of children with an anti-HBs titer of greater than 100 IU/liter in each group showed a reverse trend in magnitude.
To study whether the hampered immunologic response to HBV vaccine is due to a general deficiency in B cell immunity, we measured antibodies against JEV and diphtheria. Contrary to the immunologic response to HBV vaccine, the levels of antibody against either JEV or diphtheria did not show any significant correlation with the parental origins of these children (table 4) , nor did they show any significant correlation with the villages.
Since sex, the time elapsed since the last dose of HBV vaccine was received, and die age when the first HBV vaccine was received were three important factors that might influence the anti-HBs titers (M. S. Ho, unpublished data) and uheir differentia] distributions in the ethnic groups might have contributed to the differential anti-HBs titers between the ethnic groups, the distributions of anti-HBs titer were further analyzed according to these factors (table 5) . With such stratification analysis to control all of tiiese factors, the pure aboriginal children consistently had significantly lower anti-HBs titers than did the pure Han children in each category. A multiple linear regression model was constructed to examine these factors simultaneously (table 6) . Despite high correlation between parental origins of these children (aboriginal vs. Han) and the ethnic designation of villages (aboriginal vs. Han), parental origin consistently offered a stronger input than did the village in determining the level of antiHBs in all models (best model shown only). The mean anti-HBs titer in the pure Han children was estimated to be 12.2 IU/liter higher than that in the pure aboriginal children when all other factors were controlled for in these models.
DISCUSSION
To our knowledge, this is the first time well-defined ethnic groups have been reported to be predisposed to hyporesponsiveness to HBV vaccine. Although data on the initial response of each child to HBV vaccine were not available, studies have shown that the postvaccination residual anti-HBs concentration reflects the initial response to the vaccine (3, 5, 17, 18) and that the rate of anti-HBs degradation did not differ with different ethnic groups (19) . A higher rate of hyporesponders to HBV vaccine in a population may be due to causes in the following two major categories: 1) factors pertaining to the vaccine, including intrinsic nature of the vaccine preparation (20) (21) (22) , the site and route of vaccine administration (8, 23) , the dose (24, 25) , and conditions of vaccine storage (7), and 2) factors pertaining to the host, such as immunosuppression (10, 26, 27) , obesity (12, 28) , advanced age (7), alcohol consumption (6, 29) , smoking (8), and HLA haplotype or other genetic host determinants (12, 24, 30) . Since all of our study subjects received vaccines that were made by the same manufacturers and administered according to the manufacturer's recommended site and route, intrinsic differences between various vaccine preparations were unlikely to play an important role in this study. The evaluation of cold chain operation in this study was mainly designed for live viral vaccines, whose potency decreases with a rise in the ambient temperature. The potency of HBV vaccine, being protein in nature, may be more sensitive to freezing and thawing (7) . In the more remote villages, vaccines were transported to the clinic on the day of vaccine administration in an insulated cooler containing ice cubes; therefore, inappropriate freezing of the vaccine was unlikely to occur. Moreover, the immunologic response to JEV and diphtheria vaccines showed no significant difference between villages that would indicate problems in the logistics of immunization and vaccine delivery. We therefore conclude that factors related to the vaccine were unlikely to be the reasons for the consistently higher proportion of vaccinated aboriginal children being hyporesponsive to HBV vaccines.
The precise biologic bases for such an immunologic difference between the ethnic groups are not known at the moment, but the determinant for hyporesponsiveness to HBV vaccination is distinct from that of the JEV and diphtheria vaccines in this study and from that of the tetanus vaccine in another study (30) . Host factors pertaining to HLA haplotypes, e.g., homozygous [HLA-B8,SCO1,DR3] and [HLA-B44, FC31, DR7], have been shown to be associated with a lower immune response to HBV vaccine (24, 30) . Whether the fact that aboriginal populations possess a higher percentage of the above haplotypes could explain their immunologic responses to HBV vaccines remains to be clarified.
In our study, children who tested positive for HBsAg or antibody against core antigen, both signifying a positive history of natural infection, were excluded from the analysis because infection would influence the anti-HBs titer (data not shown). Recent studies suggest that natural HBV infection among the vaccines would be more likely to occur in those with a lower anti-HBs titer (17) . Therefore, exclusion of vaccinated children who had acquired a natural HBV infection, i.e., 13.7 percent pure aboriginal children (4.8 percent HBsAg carriers) versus 5.7 percent pure Han children (2.4 percent HBsAg carriers) might have selectively excluded more aboriginal children with lower anti-HBs response and therefore might result in an underestimation of the differences between the Han and aboriginal children.
Although only one third of mothers whose HBsAg serologic status at the time of childbirth were recorded in our study, the high HBsAg carrier rate of 28.5 percent in the mothers with aboriginal origin is in sharp contrast to the 5.8 percent in the mothers with Han origin in our study. A similarly much higher HBsAg positive rate in the aboriginal population than in the nonaboriginal population has been reported in several other studies (31, 32) . It has also been noted that children born to HBsAg carrier mothers mount a lower titer of anti-HBs when vaccinated with HBV vaccine (Ho et al., manuscript in preparation). In another study, children born to carrier mothers who possessed antibody against hepatitis B e antigen were shown to mount a better immunologic response to HBV vaccine than were children born to other carrier mothers (33) . Whether the higher rate of aboriginal children born to carrier mothers could explain their lower immunologic response to HBV vaccine than the Han children exhibited needs elucidation.
Regardless of the biologic basis for this hyporesponsiveness of aboriginal children, our observation of" the discrepancy between ethnic groups in immunologic response to HBV vaccine should be further substantiated by prospective studies to evaluate the primary response to HBV. Our recognition of this character- istic among ethnic groups that are well defined by their geographic residence, if verified, could provide an opportunity for targeted efforts to systematically seek ways to improve HBV vaccine efficacy, either by administering a higher dosage or by increasing the number of vaccine doses (24, 25) .
